The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
 
Erlinda Maria Gordon
Employment - Counterpoint Biomedica
Stock and Other Ownership Interests - Counterpoint Biomedica
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - AADi; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Counterpoint Biomedica
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Katherine Kim
No Relationships to Disclose
 
Seiya Liu
No Relationships to Disclose
 
Nicole Angel
No Relationships to Disclose
 
Rekha Baby
No Relationships to Disclose
 
Don Brigham
No Relationships to Disclose
 
William W. Tseng
No Relationships to Disclose
 
Seth Pollack
No Relationships to Disclose
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Noah Federman
Stock and Other Ownership Interests - Reata Pharmaceuticals
Consulting or Advisory Role - Bayer; Loxo; Zelda Therapeutics
Speakers' Bureau - Bayer
 
Amor M. Srikureja
No Relationships to Disclose
 
John Jalas
No Relationships to Disclose
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma